Consequently, targeting Jak2 and BCR-ABL kinases with ON044580 has the potential to manage multiple types of drug-resistant CML cells where tyrosine kinase inhibitors are not clinically useful. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.